301 results
Page 5 of 16
8-K
EX-99.1
6jnwjt7814od9cesy7
28 May 20
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
11:50am
8-K
EX-99.1
ygny0g2z5etluq
27 May 20
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
11:07am
8-K
EX-10.1
s2f20jr wr
27 May 20
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
11:07am
8-K
EX-99.1
aolvxxeh
19 May 20
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
9:28am
8-K
EX-10.1
hni81s7
19 May 20
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
9:28am
8-K
EX-10.1
1a3d04 v236i78x6dno
13 May 20
Entry into a Material Definitive Agreement
10:59am
8-K
EX-10.2
tr1l2m9 6d8hhka9rz
13 May 20
Entry into a Material Definitive Agreement
10:59am
8-K
EX-99.1
sh7azm7u5ypu
13 May 20
Entry into a Material Definitive Agreement
10:59am
8-K
EX-99.1
lk7ou01zk8maj0de
7 May 20
Trovagene Announces First Quarter 2020 Results and Highlights
4:02pm
8-K
EX-99.1
xyxjvhc5 8i6ecf6s
6 May 20
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
10:29am
8-K
EX-99.01
ek962wo
28 Apr 20
Other Events
12:22pm
8-K
EX-99.01
myv7gtc8phsdd90
22 Apr 20
Other Events
10:54am
8-K
EX-10.1
4pvucyul
10 Apr 20
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
flcty4ss s74ob4h
1 Apr 20
Other Events
1:54pm
8-K
EX-10.1
ayqadsxygls
31 Mar 20
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.1
jvp a2u3k
5 Mar 20
Trovagene Announces Three New Nominees for Election to Board of Directors
10:38am
8-K
EX-99.1
dua20z9
27 Feb 20
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
4:15pm
8-K
EX-99.1
gipvkmr5pj93m5y
13 Feb 20
Other Events
10:00am